

wherein the optional substituents are defined above for the one or more substituents.

53. (New) The pharmaceutical composition according to claim 41, which further comprises at least one compound selected from the group consisting of a prostanoid, dopamine receptor antagonist melanocortin receptor agonist, endothelin receptor antagonist, endothelin converting enzyme inhibitor, angiotensin II receptor antagonist, angiotensin converting enzyme inhibitor, neutral metalloendopeptidase inhibitor, renin inhibitor, serotonin 5-HT<sub>2c</sub> receptor agonist, nociceptin receptor agonist, rho kinase inhibitor, potassium channel modulator and multidrug resistance protein 5 inhibitor.

(54) (New) The pharmaceutical composition according to claim 53 where the second compound is an endothelin receptor antagonist.

#### REMARKS

This invention relates to polycyclic nucleotide xanthine phosphodiesterase V inhibitors, processes for their preparation and uses to treat various disease states.

The Examiner is thanked for the allowance of claims 2, 4 -12, 22, 23, 34, 41, 42, 45 and 46.

This Amendment cancels claims 52 in favor of claims 2 and changes those claims dependent therefrom, without prejudice. Applicants are canceling this claim in order to correct a typographical error made in claim 52 in the last amendment; viz. the various divalent variables found on page 7, line 3 and 4 of

he last amendment should be under the R<sup>3</sup> definition defining Y and not under R<sup>1</sup> and R<sup>2</sup>. Applicant's representative apologizes for any inconveniences that this may have caused. Support for this change is found, for example on page 21, lines 1 and 2 of the specification. This Amendment also adds claims 52 and 53. Support for these claims is found, for example, in claim 39.

**Authorization**

The Commissioner is authorized to charge any fee associated with this Amendment to render the Amendment timely filed to Deposit Account No. 19-0365.


Claim 3 is objected to for failing to limit the subject matter of the previous claim. As this claim now depends on claim 52, it is argued that this objection is moot and should be withdrawn. Applicants thank the Examiner for bringing this to their attention.

Claim 39 stands rejected under 35 USC 112, first and second paragraphs while Applicants do not concur with the rejection, they have cancelled the language the Examiner found objectionable in order to advance prosecution.

It is believed that this application is now in condition for allowance and an early notice to that effect is earnestly solicited. If, however, there remains an issue outstanding, the Examiner is invited to contact the undersigned for its prompt resolution.

Favorable action is earnestly solicited.

Respectfully submitted,



Mark W. Russell  
Registration No. 37,514  
Attorney for Applicants  
Tel: 908-298-5024  
Fax: 908-298-5388